DE60134349D1 - Synergistische Kombinationen enthaltend einen Renininhibitor für Kardiovaskulären Erkrankungen - Google Patents

Synergistische Kombinationen enthaltend einen Renininhibitor für Kardiovaskulären Erkrankungen

Info

Publication number
DE60134349D1
DE60134349D1 DE60134349T DE60134349T DE60134349D1 DE 60134349 D1 DE60134349 D1 DE 60134349D1 DE 60134349 T DE60134349 T DE 60134349T DE 60134349 T DE60134349 T DE 60134349T DE 60134349 D1 DE60134349 D1 DE 60134349D1
Authority
DE
Germany
Prior art keywords
renin inhibitor
cardiovascular diseases
combinations containing
synergistic combinations
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60134349T
Other languages
German (de)
English (en)
Inventor
William Hewitt
Daniel Lucius Vasella
Randy Lee Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60134349(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60134349D1 publication Critical patent/DE60134349D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
DE60134349T 2000-11-17 2001-11-15 Synergistische Kombinationen enthaltend einen Renininhibitor für Kardiovaskulären Erkrankungen Expired - Lifetime DE60134349D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0028151A GB0028151D0 (en) 2000-11-17 2000-11-17 Combination of organic compounds

Publications (1)

Publication Number Publication Date
DE60134349D1 true DE60134349D1 (de) 2008-07-17

Family

ID=9903412

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60134349T Expired - Lifetime DE60134349D1 (de) 2000-11-17 2001-11-15 Synergistische Kombinationen enthaltend einen Renininhibitor für Kardiovaskulären Erkrankungen
DE2001617295 Expired - Lifetime DE60117295T2 (de) 2000-11-17 2001-11-15 Synergistische kombinationen mit einem renin-inhibitor für kardiovaskuläre erkrankungen
DE200912000021 Pending DE122009000021I1 (de) 2000-11-17 2001-11-15 Synergistische Kombinationen enthaltend einen Renininhibitor für kardiovaskuläre Erkrankungen

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE2001617295 Expired - Lifetime DE60117295T2 (de) 2000-11-17 2001-11-15 Synergistische kombinationen mit einem renin-inhibitor für kardiovaskuläre erkrankungen
DE200912000021 Pending DE122009000021I1 (de) 2000-11-17 2001-11-15 Synergistische Kombinationen enthaltend einen Renininhibitor für kardiovaskuläre Erkrankungen

Country Status (31)

Country Link
US (4) US8168616B1 (https=)
EP (7) EP1602370B1 (https=)
JP (6) JP2004513920A (https=)
KR (6) KR20030051753A (https=)
CN (4) CN100404024C (https=)
AT (2) ATE317692T1 (https=)
AU (2) AU2002223680B2 (https=)
BR (1) BR0115411A (https=)
CA (2) CA2428647A1 (https=)
CY (5) CY1105603T1 (https=)
CZ (2) CZ299749B6 (https=)
DE (3) DE60134349D1 (https=)
DK (3) DK1341533T3 (https=)
EC (1) ECSP034603A (https=)
ES (4) ES2429292T3 (https=)
GB (1) GB0028151D0 (https=)
HU (2) HU230882B1 (https=)
IL (3) IL155707A (https=)
LU (2) LU91563I2 (https=)
MX (1) MXPA03004358A (https=)
NL (2) NL300385I1 (https=)
NO (2) NO334002B1 (https=)
NZ (6) NZ537691A (https=)
PL (3) PL400915A1 (https=)
PT (3) PT1341533E (https=)
RU (2) RU2310443C2 (https=)
SG (1) SG135969A1 (https=)
SI (3) SI1915993T1 (https=)
SK (1) SK287881B6 (https=)
WO (1) WO2002040007A1 (https=)
ZA (1) ZA200303497B (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005509631A (ja) * 2001-10-18 2005-04-14 ノバルティス アクチエンゲゼルシャフト Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩
BR0310084A (pt) 2002-05-17 2005-02-15 Novartis Ag Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
CA2490811A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Use of organic compounds
PT1517682E (pt) * 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
JP4884230B2 (ja) 2003-11-26 2012-02-29 ノバルティス アーゲー 有機化合物
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
ATE472524T1 (de) * 2004-01-23 2010-07-15 Novartis Ag Diaminoalkohole und deren verwendung als renininhibitoren
EP1711456A2 (en) * 2004-01-23 2006-10-18 Speedel Experimenta AG Amino alcohol derivatives and their use as renin inhibitors
BRPI0506491A (pt) * 2004-01-23 2007-02-13 Speedel Experimenta Ag compostos orgánicos
PE20142101A1 (es) * 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
NZ549535A (en) * 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders
TW200609215A (en) 2004-03-19 2006-03-16 Speedel Experimenta Ag Organic compounds
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
ES2384637T3 (es) * 2004-10-08 2012-07-10 Novartis Ag Uso de inhibidores de la renina para la prevención o el tratamiento de disfunción diastólica o insuficiencia cardiaca diastólica
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
EP1897879A3 (en) 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-substituted piperidines as renin inhibitors
US20090247582A1 (en) * 2005-04-27 2009-10-01 Randy Lee Webb Methods of treating atherosclerosis
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
CN1732952B (zh) * 2005-09-02 2010-04-07 姚俊华 一种治疗高血压的复方分散片
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
DE602005005706T2 (de) * 2005-09-28 2009-04-16 Teva Pharmaceutical Industries Ltd. Stabile Arzneimittelkombinationen von Amlodipinbesylat und Benazeprilhydrochlorid
KR20080066776A (ko) * 2005-11-08 2008-07-16 노파르티스 아게 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
JP2009530284A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド 拡張期心不全を治療するための方法と組成物
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
US20100029775A1 (en) * 2006-12-15 2010-02-04 Prescott Margaret F Renin inhibitors for the prevention and treatment of hypertension in obese patients
US20080194626A1 (en) * 2007-02-14 2008-08-14 Gorczynski Richard J Antihypertensive drug combination
US20100209480A1 (en) * 2007-09-28 2010-08-19 Ralf Altenburger Galenical formulations of organic compounds
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
WO2009104939A2 (ko) 2008-02-22 2009-08-27 한올제약주식회사 약제학적 제제
US20110111022A1 (en) 2008-04-10 2011-05-12 Hanall Biopharma Co., Ltd. Pharmaceutical formulation
WO2009127251A1 (en) * 2008-04-16 2009-10-22 Novartis Ag Combinations comprising a renin inhibitor
KR101209319B1 (ko) 2008-04-29 2012-12-06 한올바이오파마주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
EP2189442B1 (en) 2008-11-20 2014-10-01 Krka Tovarna Zdravil, D.D., Novo Mesto Process and intermediates for the preparation of aliskiren
EP2408427A1 (en) 2009-03-20 2012-01-25 Novartis AG Galenical formulations of a fixed dose combination of valsartan and aliskiren
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
EP2704706A1 (en) 2011-05-06 2014-03-12 Artskin D.O.O. Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
RU2483750C1 (ru) * 2012-03-19 2013-06-10 Общество с ограниченной ответственностью "СупраГен" Способ лечения больных с острым инфарктом миокарда с подъемом сегмента st
EP3682902A1 (en) * 2012-05-18 2020-07-22 Luoda Pharma Limited Liquid formulation
RU2554815C1 (ru) * 2014-06-18 2015-06-27 Общество с ограниченной ответственностью "Нанолек" Гипотензивное средство
DK3174530T3 (en) 2014-07-30 2018-11-26 Merck Patent Gmbh DIRECT COMPATIBLE POLYVINYL ALCOHOLS
KR102923585B1 (ko) * 2016-10-27 2026-02-04 다미안 파르마 에이쥐 알도스테론 합성효소 저해제

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
FI77669C (fi) 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4782043A (en) 1983-06-15 1988-11-01 Merck & Co., Inc. Renin inhibitors containing a C-terminal amide cycle
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4812442A (en) 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
SE8802428D0 (sv) * 1988-06-28 1988-06-28 Haessle Ab New compounds
US5268374A (en) 1988-10-04 1993-12-07 Abbott Laboratories Non-peptide renin inhibitors
US5164388A (en) 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
DK0403159T3 (da) 1989-06-14 2000-08-14 Smithkline Beecham Corp Imidazolylalkensyrer
EP0438311A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Di- and tripeptide renin inhibitors
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
TW201738B (https=) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
DK0527879T3 (da) * 1990-05-11 1997-07-14 Pfizer Synergistiske terapeutiske præparater og fremgangsmåder.
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
WO1992000972A1 (en) 1990-07-11 1992-01-23 Abbott Laboratories Renin inhibiting compounds
CA2089268A1 (en) * 1990-08-15 1992-02-16 William R. Baker Renin inhibitors
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
KR100222252B1 (ko) * 1990-12-14 1999-10-01 스튜어트 알. 수터 안지오텐신 ii 수용체 차단 조성물
AU1256692A (en) 1991-02-06 1992-09-07 Schering Corporation Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
TW226375B (https=) 1991-10-24 1994-07-11 American Home Prod
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
EP0699069B9 (en) 1993-04-27 2003-10-22 Smithkline Beecham Corporation Endothelin receptor antagonists
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
PT634175E (pt) * 1993-07-15 2001-06-29 Hoffmann La Roche Combinacao farmaceutica que contem um inibidor do sistema renina-angiotensina e o antagonista de endotelina
AU675870B2 (en) 1993-08-18 1997-02-20 Msd K.K. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5562921A (en) 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
WO1996006095A1 (en) 1994-08-19 1996-02-29 Abbott Laboratories Endothelin antagonists
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TW313568B (https=) 1994-12-20 1997-08-21 Hoffmann La Roche
PL184060B1 (pl) 1995-01-27 2002-08-30 Rhone Poulenc Rorer Ltd Podstawione związki fenylowe do zastosowania jako środki antagonistyczne endoteliny
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
JP3087968B2 (ja) 1995-12-20 2000-09-18 山之内製薬株式会社 アリールエテンスルホンアミド誘導体及びその医薬組成物
IT1277737B1 (it) 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
WO1997027314A1 (fr) 1996-01-23 1997-07-31 Shionogi & Co., Ltd. Processus de production d'analogues d'acide oleanolique par la culture de racine pileuse
EP0906108B1 (en) 1996-04-04 2005-06-15 Banyu Pharmaceutical Co., Ltd. Endothelin antagonists for treating heart failure
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
AU750122C (en) * 1998-06-17 2003-02-27 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of ADP-receptor antiplatelet and antihypertensive drugs in combination
NZ509378A (en) 1998-07-20 2003-04-29 Smithkline Beecham Corp Amorphous ammonium salts of eprosartan and pharmaceuticals thereof, useful for blocking angiotensin II receptors and useful for treating hypertension, congestive heart disease and renal failure
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
CA2368187A1 (en) * 1999-03-19 2000-09-28 Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
CA2390561A1 (en) 1999-11-09 2001-05-17 Pharmacia Corporation Use of an aldosterone antagonist for treating restenosis
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
BR0310084A (pt) 2002-05-17 2005-02-15 Novartis Ag Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético
ATE397147T1 (de) 2002-12-31 2008-06-15 Volkswagen Ag Verfahren zur steuerung einer verbrennungskraftmaschine sowie magerlauffahige verbrennungskraftmaschine

Also Published As

Publication number Publication date
RU2310443C2 (ru) 2007-11-20
DE122009000021I1 (de) 2009-08-06
JP2017019876A (ja) 2017-01-26
NO334002B1 (no) 2013-11-11
HK1059212A1 (en) 2004-06-25
SK5842003A3 (en) 2003-11-04
KR101258365B1 (ko) 2013-04-30
DK1915993T3 (da) 2013-10-14
SI1341533T1 (sl) 2006-08-31
CY1105603T1 (el) 2010-07-28
NO20032233L (no) 2003-05-16
US8168616B1 (en) 2012-05-01
SI1915993T1 (sl) 2013-10-30
EP2305231A1 (en) 2011-04-06
RU2346703C2 (ru) 2009-02-20
JP6603757B2 (ja) 2019-11-06
KR20030051753A (ko) 2003-06-25
EP1602370A3 (en) 2005-12-14
IL217847A0 (en) 2012-03-29
HU1400409D0 (hu) 2003-09-29
MXPA03004358A (es) 2003-08-19
CZ299749B6 (cs) 2008-11-12
NZ525795A (en) 2005-03-24
PL361404A1 (en) 2004-10-04
EP1602370A2 (en) 2005-12-07
JP2018030894A (ja) 2018-03-01
HUP0301841A2 (hu) 2003-09-29
DE60117295D1 (de) 2006-04-20
CN1474690A (zh) 2004-02-11
IL155707A0 (en) 2003-11-23
US9023893B2 (en) 2015-05-05
KR20080011355A (ko) 2008-02-01
CY2013045I2 (el) 2015-11-04
US20120010295A1 (en) 2012-01-12
NL301005I2 (nl) 2019-10-29
LU92315I2 (fr) 2014-01-27
ATE317692T1 (de) 2006-03-15
SI1602370T1 (sl) 2008-10-31
KR20080096715A (ko) 2008-10-31
CA2763223A1 (en) 2002-05-23
EP1930000A1 (en) 2008-06-11
DK1602370T3 (da) 2008-09-22
ECSP034603A (es) 2003-06-25
ES2308347T3 (es) 2008-12-01
EP2305233A1 (en) 2011-04-06
PT1602370E (pt) 2008-09-10
ATE397445T1 (de) 2008-06-15
IL212075A (en) 2013-08-29
IL155707A (en) 2012-02-29
CA2428647A1 (en) 2002-05-23
IL212075A0 (en) 2011-06-30
NZ550897A (en) 2008-03-28
KR20110063596A (ko) 2011-06-10
NL300385I1 (nl) 2009-07-01
CZ305341B6 (cs) 2015-08-05
NZ550896A (en) 2008-06-30
PT1915993E (pt) 2013-10-14
US8618174B2 (en) 2013-12-31
BR0115411A (pt) 2004-08-17
WO2002040007A1 (en) 2002-05-23
KR20100114904A (ko) 2010-10-26
JP2018131465A (ja) 2018-08-23
RU2006132668A (ru) 2008-03-20
NZ537691A (en) 2007-01-26
NO2013019I2 (no) 2013-12-17
JP2004513920A (ja) 2004-05-13
EP1341533A1 (en) 2003-09-10
PL400915A1 (pl) 2012-12-17
AU2002223680B2 (en) 2005-04-07
CY1108305T1 (el) 2012-01-25
JP2013213061A (ja) 2013-10-17
NL301005I1 (https=) 2019-09-10
NZ550898A (en) 2008-07-31
CN101091703A (zh) 2007-12-26
US9023894B2 (en) 2015-05-05
DK1341533T3 (da) 2006-05-08
US20120016035A1 (en) 2012-01-19
NO2013019I1 (no) 2014-06-02
KR20080097488A (ko) 2008-11-05
GB0028151D0 (en) 2001-01-03
CY2009005I2 (el) 2012-01-25
JP6373931B2 (ja) 2018-08-15
EP2305232B1 (en) 2019-07-17
JP6089278B2 (ja) 2017-03-08
ZA200303497B (en) 2004-04-28
ES2429292T3 (es) 2013-11-14
EP1341533B1 (en) 2006-02-15
PL227576B1 (pl) 2017-12-29
CY2009005I1 (el) 2012-01-25
US20120004312A1 (en) 2012-01-05
ES2734523T3 (es) 2019-12-10
CN101264073A (zh) 2008-09-17
HUP0301841A3 (en) 2010-07-28
HU230882B1 (hu) 2018-11-29
HK1115544A1 (en) 2008-12-05
HK1089356A1 (en) 2006-12-01
CY1114829T1 (el) 2015-11-04
KR101008752B1 (ko) 2011-01-14
DE60117295T2 (de) 2006-08-17
ES2256335T3 (es) 2006-07-16
JP2009235107A (ja) 2009-10-15
EP2305232A1 (en) 2011-04-06
CY2013045I1 (el) 2015-11-04
CN100404024C (zh) 2008-07-23
EP1602370B1 (en) 2008-06-04
SK287881B6 (sk) 2012-02-03
EP1915993B1 (en) 2013-07-10
CN101264072A (zh) 2008-09-17
PT1341533E (pt) 2006-06-30
NO20032233D0 (no) 2003-05-16
JP6577994B2 (ja) 2019-09-18
PL400914A1 (pl) 2012-12-17
AU2368002A (en) 2002-05-27
LU91563I2 (fr) 2009-07-06
SG135969A1 (en) 2007-10-29
NZ568764A (en) 2009-11-27
EP1915993A1 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
ATE397445T1 (de) Synergistische kombinationen enthaltend einen renininhibitor für kardiovaskulären erkrankungen
EP1734041A3 (en) Platelet ADP receptor inhibitors
HUP0102281A3 (en) Prodrugs of dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
HUP0200347A3 (en) N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use
BG106586A (en) Pyrazolopyramidines as therapeutic agents
HUP0401567A3 (en) Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
MXPA03010761A (es) Combinaciones farmaceuticas.
NO985116D0 (no) Sammensetning som omfatter en KATP kanalhemmer for anvendelse i behandling av hemoragisk sjokk
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
MXPA04005226A (es) 1,3-diarilprop-2-en-1-onas, composiciones que las contienen y su utilizacion.
ITMI931806A0 (it) Composti inibitpri di acil enzima-a-colesterolo-o-acil transferasi ad attivita' terapeutica , loro uso e composizioni farmaceutiche che li contengono
EP1452522A3 (en) Novel compounds and compositions as protease inhibitors
GB2287938B (en) Conformationally restricted HIV-1 protease inhibitors
ITTO20001109A0 (it) Composizione farmaceutica per il trattamento anti m. ulcerans.
GEP20032923B (en) Sulphonamide Derivatives as Prodrugs of Aspartyl Protease Inhibitors, Pharmaceutical compositions containing the Same and Methods for Treatment
RU2000128859A (ru) Способ защиты печени от ксенобиотиков в эксперименте

Legal Events

Date Code Title Description
V448 Application of spc

Free format text: PRODUCT NAME: KOMBINATION VON ALISKIREN ALS DIE FREIE BASE ODER ALS EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON UND VON HYDROCHLORTHIAZID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ HIERVON; REGISTRATION NO/DATE: EU/1/08/491/001-080, 20090116

Spc suppl protection certif: 12 2009 000 021

Filing date: 20090422

8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS PHARMA AG, BASEL, CH

R065 Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: KOMBINATION VON ALISKIREN ALS DIE FREIE BASE ODER ALS EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON UND VON HYDROCHLORTHIAZID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ HIERVON; NAT. REGISTRATION NO/DATE: EU/1/08/491/001-080 20090116 FIRST REGISTRATION: SCHWEIZ CH 58935 01 CH 58935 02 CH 58935 03 CH 58935 04 20081028

Spc suppl protection certif: 122009000021

Filing date: 20090422

Expiry date: 20211116

Effective date: 20090518

8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN

R067 Examining division decision granting supplementary protection certificate

Free format text: PRODUCT NAME: KOMBINATION VON ALISKIREN ALS DIE FREIE BASE ODER ALS EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON UND VON HYDROCHLORTHIAZID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ HIERVON; NAT. REGISTRATION NO/DATE: EU/1/08/491/001-080 20090116 FIRST REGISTRATION: SCHWEIZ CH 58935 01 CH 58935 02 CH 58935 03 CH 58935 04 20081028

Spc suppl protection certif: 122009000021

Filing date: 20090422

Expiry date: 20211116

Extension date: 20231028

R069 Supplementary protection certificate granted

Free format text: PRODUCT NAME: KOMBINATION VON ALISKIREN ALS DIE FREIE BASE ODER ALS EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON UND VON HYDROCHLORTHIAZID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ HIERVON; NAT. REGISTRATION NO/DATE: EU/1/08/491/001-080 20090116 FIRST REGISTRATION: SCHWEIZ CH 58935 01 CH 58935 02 CH 58935 03 CH 58935 04 20081028

Spc suppl protection certif: 122009000021

Filing date: 20090422

Expiry date: 20211116

Extension date: 20231028

Effective date: 20120720